Posted in | News | Chemical Sensor

Identa’s U.S. Rep Confirms Presentation on Explosive Detection in the U.S.

Jant Pharmacal Corporation, the U.S. representative of Jerusalem-based IDenta Corp., has reported that a Chicago-based, large multinational client has confirmed the presentation/conference on explosive detection on 19 March in the U.S.

Identa's New Explosive Product Line

Around 40 State, County, Municipal, Private and Federal Agencies decision makers have so far signed up for the presentation. The local FBI bomb unit is coordinating the presentation. The bomb unit has also purchased kits for evaluation and reported positive feedback about the kits being the best in the market.

Jant has also reported that it has dispatched the Ammonium Test kits, known as EX377, to contacts including GE, Naval EOD Technology Division, ATF, and TSA and some contacts in the testing sites of the U.S. Army. Jant is planning to follow up with these contacts next week. The EX377 kit is a novel identifying explosive kit that was developed in Afghanistan for the U.S. Army by Baruch Glattstein.

About 30 minutes time has been earmarked for the presentation by Jant Pharmacal. during the conference. Jant will email a copy of its presentation in powerpoint format
to Glattstein for suggestions, remarks, and approval.

Jant has also reported that the fate of a tender to IDenta to supply 100,000 explosive kits to the U.S. Army would be known this week. IDENTA is confident of being awarded this contract being the only company that could offer the EX377 test kit.

Yaacov Shoham, CEO of IDenta, revealed that such activities related to the supply of explosive kits is only part of IDenta activities worldwide. Shoham added that there has been a tremendous acceptance for the kits from its customers.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.